ClinicalTrials.gg
CompletedNCT02155660TERRANOVAUpdated Jun 26, 2019Results posted

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

A Phase 3 interventional study of Benralizumab Arm A and Benralizumab Arm B in Moderate to Very Severe Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 356 sites in 26 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-26.

Primary conditionPulmonary Disease, Chronic ObstructiveRegistry: Lung Diseases, ObstructiveReclassifiedWhy we changed it
Registry
Lung Diseases, Obstructive — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Disease, Chronic Obstructive
Why
  1. The study's listed conditions name Pulmonary Disease, Chronic Obstructive, a narrower term within Lung Diseases, Obstructive.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,255
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
7th of 194
2,255 · median 137
Started
2014
with 13 others
Phase 3
76 of 284
4 open now
Registered
152nd of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 7th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2014, is one of 76 in phase 3, and was the 152nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.

03

Conditions studied

  • Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Keywords

  • Obstructive Lung Diseases
  • Chronic Obstructive Pulmonary Disease
  • Lung Disease
  • Bronchial Diseases
  • COPD Exacerbation
  • Respiratory Tract Diseases
04

In context

Pulmonary Disease, Chronic Obstructive Reclassified

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

This study's enrollment of 2,255 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Compared within Pulmonary Disease, Chronic Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases, Obstructive. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:.

  • .
  • Subjects 40-85 y.o.
  • Moderate to very severe with Post Bronchodilator (BD) >20% and ≤65%.

    -≥2 moderate or ≥1 severe COPD exacerbation(s) required treatment or hospitalization within 2-52 weeks prior to Visit1.

  • Modified Medical Research Council (mMRC) score ≥1 at Visit 1.
  • Treatment with double or triple therapy throughout the year prior to Visit 1, constant 2 weeks prior to Visit 1.
  • Tobacco history of ≥10 pack-years.
  • Women of must use a highly effective form of from Visit 1 until 16 weeks after their last dose, and negative serum pregnancy test result at Visit 1.
  • Male subjects who are sexually active must be surgically sterile one year prior to Visit 1 or use an adequate method of contraception from the first Product (IP) dose until 16 weeks after their last dose.
  • Compliance with maintenance therapy during run-in ≥70%.
  • Blood eosinophils due to subject's stratification and cap for blood eosinophil levels.When any eosinophil cohort is full, subjects in the completed cohort will not be randomised and will be withdrawn from the study.

Exclusion criteria:

  • pulmonary disease other than COPD or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
  • Any disorder or major physical impairment that is not stable by Investigator opinion and/or could affect: - subject safety-study findings or their interpretation or subject's ability to complete the entire study duration.
  • Unstable ischemic heart disease, arrhythmia, cardiomyopathy, or other relevant cardiovascular disorder that in Investigator's judgment may put the patient at risk or negatively affect the study outcome.
  • Treatment with systemic and/or antibiotics, and/or hospitalization for a COPD exacerbation within 2 weeks prior to Visit1 or during the enrolment and run-in period.
  • Acute upper or lower respiratory infection requiring antibiotics within 2 weeks prior to Visit1 or during the enrolment and run-in period.
  • Pneumonia within 8 weeks prior to Visit1 or during the enrolment and run-in period.
  • Pregnant, breastfeeding, or lactating women.
  • Risk factors for pneumonia
  • History of anaphylaxis to any other biologic therapy.
  • Long term oxygen therapy with signs and/or symptoms of cor pulmonale, right ventricular failure.
  • Use of medication within 2 weeks prior to Visit1 and/or during the enrolment and run-in period.
  • Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to Visit 1.
  • Evidence of active tuberculosis (TB) without an appropriate course of treatment.
  • Lung volume reduction surgery within the 6 months prior to Visit 1. History of partial or total lung resection (single lobe or segmentectomy is acceptable).
  • Asthma as a primary or main diagnosis according to the Global Initiative for Asthma (GINA) guidelines or other accepted guidelines.
  • Previous treatment with benralizumab.
  • Helminth parasitic infection diagnosed within 24 weeks prior to Visit 1.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,255 participants (actual)

Study arms

  • Experimental
    Benralizumab Arm A

    Benralizumab administered subcutaneously

    Drug: Benralizumab Arm A

  • Experimental
    Benralizumab Arm B

    Benralizumab administered subcutaneously

    Drug: Benralizumab Arm B

  • Experimental
    Benralizumab Arm C

    Benralizumab administered subcutaneously

    Drug: Benralizumab Arm C

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously

    Drug: Placebo

Interventions

  • DrugBenralizumab Arm A

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

  • DrugBenralizumab Arm B

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

  • DrugBenralizumab Arm C

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

  • DrugPlacebo

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

07

What researchers measure

Primary outcomes

  1. Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

    A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

    Time frame: Immediately following the first IP dose through week 56

Secondary outcomes

  1. Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL

    A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

    Time frame: Immediately following the first IP dose through week 56

  2. Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL

    Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.

    Time frame: First IP up to end of treatment Week 56

  3. Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL

    SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.

    Time frame: First IP up to Week 56

  4. Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL

    CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.

    Time frame: First IP up to Week 56

  5. Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL

    The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.

    Time frame: First IP up to Week 56

  6. Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL

    The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.

    Time frame: First IP up to Week 56

  7. Mean Change From Baseline in Proportion of Nights With Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL

    Change from baseline to Week 56 in proportion of nights with awakenings due to respiratory symptoms.

    Time frame: First IP up to Week 56

  8. Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS>=220/uL

    The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences "today". The daily EXACT-PRO total score is recorded and has a range of 0-100 with higher scores indicative of greater severity. COPD exacerbation event frequency is calculated based on comparison of the baseline score with daily total scores. An increase of EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicates a COPD exacerbation event has occurred.

    Time frame: Immediately following first IP up to week 56

  9. Severity of EXACT-PRO for Patients With Baseline EOS>=220/uL

    The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity of the study is the highest score of EXACT-PRO.

    Time frame: Immediately following first IP up to week 56

  10. Duration of COPD Exacerbation Based on EXACT-PRO Score for Patients With Baseline EOS>=220/uL

    The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. COPD exacerbation event frequency is identified by comparing the baseline score with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Event duration is calculated after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.

    Time frame: Immediately following first IP up to week 56

  11. Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

    The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

    Time frame: Immediately following the first IP dose through week 56

  12. Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL

    A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.

    Time frame: Immediately following first IP dose up to week 56

  13. Time to First COPD Exacerbation

    Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation.

    Time frame: Immediately following IP dose to Week 56

  14. Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

    Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

    Time frame: Immediately following the first IP dose through week 56

  15. Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS>=220/uL

    Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.

    Time frame: Immediately following first IP dose up to Week 56

  16. Duration of Study Treatment Administration

    Duration of study treatment is calculated from first dose date to last dose date + 1 day.

    Time frame: From first dose date to last dose date, 48 weeks per protocol.

  17. Serum Concentration of Benralizumab

    PK serum samples were collected pre-dose at each visit.

    Time frame: Pre-first dose and pre-dose at end of treatment (week 56).

  18. Immunogenicity of Benralizumab

    Anti-drug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented.

    Time frame: Pre-treatment until end of follow-up, week 60 per protocol.

08

Results

Posted Jun 26, 2019

Participant flow

Participant flow — Overall Study
MilestoneBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Started562562562568
Completed504489502507
Not completed58736061
Withdrew: Other reason861010
Withdrew: Study-specific withdrawal criteria0111
Withdrew: Severe non-compliance0401
Withdrew: Adverse event2631
Withdrew: Lost to follow-up3658
Withdrew: Death17191719
Withdrew: Withdrawal by subject28312421

Outcome measures

PrimaryAnnual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

Time frame:
Immediately following the first IP dose through week 56
Reported as:
Least squares mean · Exacerbations per year
Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL
Exacerbations per yearBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL0.99 (0.87 to 1.13)1.21 (1.08 to 1.37)1.09 (0.96 to 1.23)1.17 (1.04 to 1.32)
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Negative binomial · p = 0.0638 · Rate ratio: 0.85 · 95% CI 0.71 to 1.01Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = 0.6575 · Rate ratio: 1.04 · 95% CI 0.88 to 1.23Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.
  • Benralizumab 100 mg vs Placebo · Negative binomial · p = 0.3988 · Rate ratio: 0.93 · 95% CI 0.78 to 1.10Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.
SecondaryAnnual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL

A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

Time frame:
Immediately following the first IP dose through week 56
Reported as:
Least squares mean · Exacerbations per year
Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL
Exacerbations per yearBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL1.23 (1.03 to 1.46)1.27 (1.05 to 1.53)1.21 (1.00 to 1.45)1.18 (0.98 to 1.41)
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Negative binomial · p = 0.7564 · Rate ratio: 1.04 · 95% CI 0.82 to 1.32Model includes treatment group, region, background therapy, number of exacerbations in the previous year.
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = 0.5573 · Rate ratio: 1.08 · 95% CI 0.84 to 1.37Model includes treatment group, region, background therapy, number of exacerbations in the previous year.
  • Benralizumab 100 mg vs Placebo · Negative binomial · p = 0.8644 · Rate ratio: 1.02 · 95% CI 0.80 to 1.30Model includes treatment group, region, background therapy, number of exacerbations in the previous year.
SecondaryMean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL

Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.

Time frame:
First IP up to end of treatment Week 56
Reported as:
Mean · Liter
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL
LiterBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL0.021 ± 0.3460.011 ± 0.2890.033 ± 0.2910.016 ± 0.292
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Mixed Models Analysis · p = 0.5043 · Mean difference (final values): 0.015 · 95% CI -0.029 to 0.059Model includes treatment group, baseline FEV1 value, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.7691 · Mean difference (final values): -0.007 · 95% CI -0.051 to 0.037Model includes treatment group, baseline FEV1 value, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.3767 · Mean difference (final values): 0.02 · 95% CI -0.024 to 0.064Model includes treatment group, baseline FEV1 value, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryMean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL

SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.

Time frame:
First IP up to Week 56
Reported as:
Mean · Percentage
Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL
PercentageBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL-7.733 ± 14.996-8.674 ± 17.910-7.257 ± 15.989-6.863 ± 16.344
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Mixed Models Analysis · p = 0.3636 · Mean difference (final values): -1.011 · 95% CI -3.192 to 1.171Model includes treatment group, baseline SGRQ score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.2106 · Mean difference (final values): -1.388 · 95% CI -3.562 to 0.786Model includes treatment group, baseline SGRQ score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.5851 · Mean difference (final values): -0.602 · 95% CI -2.763 to 1.560Model includes treatment group, baseline SGRQ score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryMean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL

CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.

Time frame:
First IP up to Week 56
Reported as:
Mean · Score on a scale
Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL
Score on a scaleBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL-2.18 ± 6.78-2.43 ± 7.18-2.36 ± 6.67-2.36 ± 6.54
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Mixed Models Analysis · p = 0.8525 · Mean difference (final values): 0.09 · 95% CI -0.82 to 0.99Model includes treatment group, baseline CAT total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.9870 · Mean difference (final values): -0.01 · 95% CI -0.91 to 0.89Model includes treatment group, baseline CAT total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.8204 · Mean difference (final values): -0.1 · 95% CI -1.00 to 0.79Model includes treatment group, baseline CAT total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryMean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL

The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.

Time frame:
First IP up to Week 56
Reported as:
Mean · Score on a scale
Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL
Score on a scaleBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL-1.657 ± 5.701-2.219 ± 6.381-1.593 ± 5.665-1.137 ± 5.935
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Mixed Models Analysis · p = 0.2636 · Mean difference (final values): -0.4 · 95% CI -1.102 to 0.301Model includes treatment group, baseline total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.4087 · Mean difference (final values): -0.296 · 95% CI -0.998 to 0.406Model includes treatment group, baseline total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.2336 · Mean difference (final values): -0.425 · 95% CI -1.125 to 0.275Model includes treatment group, baseline total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryMean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL

The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.

Time frame:
First IP up to Week 56
Reported as:
Mean · Puffs/day
Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL
Puffs/dayBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL-0.36 ± 3.04-0.24 ± 3.36-0.17 ± 3.020.23 ± 3.55
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Mixed Models Analysis · p = 0.0012 · Mean difference (final values): -0.642 · 95% CI -1.029 to -0.254Model includes treatment group, baseline rescue med. use, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.0852 · Mean difference (final values): -0.340 · 95% CI -0.727 to 0.047Model includes treatment group, baseline rescue med. use, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.0650 · Mean difference (final values): -0.364 · 95% CI -0.750 to 0.023Model includes treatment group, baseline rescue med. use, EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryMean Change From Baseline in Proportion of Nights With Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL

Change from baseline to Week 56 in proportion of nights with awakenings due to respiratory symptoms.

Time frame:
First IP up to Week 56
Reported as:
Mean · Proportion of nights
Mean Change From Baseline in Proportion of Nights With Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL
Proportion of nightsBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Mean Change From Baseline in Proportion of Nights With Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL-0.092 ± 0.297-0.131 ± 0.332-0.084 ± 0.334-0.053 ± 0.345
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Mixed Models Analysis · p = 0.0415 · Mean difference (final values): -0.041 · 95% CI -0.081 to -0.002Model includes treatment group, baseline prop. of nights awakens., EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.0069 · Mean difference (final values): -0.055 · 95% CI -0.094 to -0.015Model includes treatment group, baseline prop. of nights awakens., EOS cohort, region, background therapy, visit, and treatment by visit interaction.
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.2008 · Mean difference (final values): -0.026 · 95% CI -0.065 to 0.014Model includes treatment group, baseline prop. of nights awakens., EOS cohort, region, background therapy, visit, and treatment by visit interaction.
SecondaryNumber of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS>=220/uL

The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences "today". The daily EXACT-PRO total score is recorded and has a range of 0-100 with higher scores indicative of greater severity. COPD exacerbation event frequency is calculated based on comparison of the baseline score with daily total scores. An increase of EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicates a COPD exacerbation event has occurred.

Time frame:
Immediately following first IP up to week 56
Reported as:
Count of participants · Participants
Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS>=220/uL
ParticipantsBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
0166173162159
1108107113119
245515646
321272527
414161313
588912
67647
72412
84121
90101
102000
110001
SecondarySeverity of EXACT-PRO for Patients With Baseline EOS>=220/uL

The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity of the study is the highest score of EXACT-PRO.

Time frame:
Immediately following first IP up to week 56
Reported as:
Mean · Score on a scale
Severity of EXACT-PRO for Patients With Baseline EOS>=220/uL
Score on a scaleBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Severity of EXACT-PRO for Patients With Baseline EOS>=220/uL50.3 ± 12.3052.1 ± 11.351.2 ± 11.051.0 ± 11.7
SecondaryDuration of COPD Exacerbation Based on EXACT-PRO Score for Patients With Baseline EOS>=220/uL

The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. COPD exacerbation event frequency is identified by comparing the baseline score with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Event duration is calculated after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.

Time frame:
Immediately following first IP up to week 56
Reported as:
Mean · Days
Duration of COPD Exacerbation Based on EXACT-PRO Score for Patients With Baseline EOS>=220/uL
DaysBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Duration of COPD Exacerbation Based on EXACT-PRO Score for Patients With Baseline EOS>=220/uL110.1 ± 114.096.1 ± 109.399.8 ± 114.899.9 ± 113.9
SecondaryAnnual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while considering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

Time frame:
Immediately following the first IP dose through week 56
Reported as:
Least squares mean · Exacerbations per year
Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL
Exacerbations per yearBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL1.20 (1.05 to 1.37)1.21 (1.06 to 1.37)1.13 (0.99 to 1.29)1.23 (1.08 to 1.40)
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Negative binomial · p = 0.8158 · Rate ratio: 0.98 · 95% CI 0.81 to 1.18Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = 0.8378 · Rate ratio: 0.98 · 95% CI 0.82 to 1.18Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.
  • Benralizumab 100 mg vs Placebo · Negative binomial · p = 0.3759 · Rate ratio: 0.92 · 95% CI 0.76 to 1.11Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.
SecondaryNumber of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL

A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.

Time frame:
Immediately following first IP dose up to week 56
Reported as:
Count of participants · Participants
Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL
ParticipantsBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL203241214208
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.9141 · Odds ratio (or): 1.02 · 95% CI 0.76 to 1.36CMH test controlling for EOS cohort, region, and background therapy.
  • Benralizumab 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0323 · Odds ratio (or): 1.39 · 95% CI 1.03 to 1.87CMH test controlling for EOS cohort, region, and background therapy.
  • Benralizumab 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.5109 · Odds ratio (or): 1.10 · 95% CI 0.82 to 1.48CMH test controlling for EOS cohort, region, and background therapy.
SecondaryTime to First COPD Exacerbation

Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation.

Time frame:
Immediately following IP dose to Week 56
Reported as:
Median · Days
Time to First COPD Exacerbation
DaysBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Time to First COPD Exacerbation315 (244 to 380)260 (225 to 291)322 (278 to 373)337 (261 to 400)
SecondaryAnnual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL

Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.

Time frame:
Immediately following the first IP dose through week 56
Reported as:
Least squares mean · Exacerbations per year
Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL
Exacerbations per yearBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL0.22 (0.17 to 0.29)0.29 (0.23 to 0.36)0.22 (0.17 to 0.28)0.32 (0.26 to 0.40)
Statistical analysis
  • Benralizumab 10 mg vs Placebo · Negative binomial · p = 0.0287 · Rate ratio: 0.68 · 95% CI 0.49 to 0.96Model includes treatment group, EOS cohort, region, background therapy, previous year exacerbations associated with hospitalization (Y/N).
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = 0.4631 · Rate ratio: 0.89 · 95% CI 0.65 to 1.22Model includes treatment group, EOS cohort, region, background therapy, previous year exacerbations associated with hospitalization (Y/N).
  • Benralizumab 100 mg vs Placebo · Negative binomial · p = 0.0185 · Rate ratio: 0.67 · 95% CI 0.48 to 0.94Model includes treatment group, EOS cohort, region, background therapy, previous year exacerbations associated with hospitalization (Y/N).
SecondaryNumber of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS>=220/uL

Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.

Time frame:
Immediately following first IP dose up to Week 56
Reported as:
Count of participants · Participants
Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS>=220/uL
ParticipantsBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Hospitalisations45674859
Emergency department49725871
Unscheduled outpatient visits208230225211
Home visits14201714
Telephone calls98112109114
Ambulance transports10192022
SecondaryDuration of Study Treatment Administration

Duration of study treatment is calculated from first dose date to last dose date + 1 day.

Time frame:
From first dose date to last dose date, 48 weeks per protocol.
Reported as:
Mean · Days
Duration of Study Treatment Administration
DaysBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
Duration of Study Treatment Administration307.4 ± 80.38302.2 ± 84.62303.0 ± 88.48308.8 ± 78.95
SecondarySerum Concentration of Benralizumab

PK serum samples were collected pre-dose at each visit.

Time frame:
Pre-first dose and pre-dose at end of treatment (week 56).
Reported as:
Geometric mean · ng/mL
Serum Concentration of Benralizumab
ng/mLBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mg
BaselineNA ± NANA ± NANA ± 51.95
Week 5642.51 ± 384.81222.92 ± 248.24594.33 ± 321.66
SecondaryImmunogenicity of Benralizumab

Anti-drug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented.

Time frame:
Pre-treatment until end of follow-up, week 60 per protocol.
Reported as:
Count of participants · Participants
Immunogenicity of Benralizumab
ParticipantsBenralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlacebo
ADA prevalence70527726
ADA incidence60396516
Both base/post-baseline positive98510
Only post baseline57386414
Only baseline4682
ADA persistently positive4230436
ADA transiently positive158218
nAb prevalence55375913
nAb incidence5033529

Adverse events

Collected over From the time patient signed informed consent throughout the treatment period to the follow-up visit (week 60).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 10 mg17/561 (3%)144/561 (25.7%)251/561 (44.7%)
Benra 30 mg21/563 (3.7%)177/563 (31.4%)233/563 (41.4%)
Benra 100 mg17/562 (3%)127/562 (22.6%)238/562 (42.3%)
Placebo19/568 (3.3%)158/568 (27.8%)260/568 (45.8%)
Most frequent serious events
Showing 10 of 270
Most frequent serious events
EventBenra 10 mgBenra 30 mgBenra 100 mgPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders92/561107/56380/56289/568
PneumoniaInfections and infestations19/56122/5639/56230/568
Acute myocardial infarctionCardiac disorders2/5617/5631/5621/568
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/5610/5633/5620/568
Pneumonia bacterialInfections and infestations5/5615/5632/5621/568
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/5611/5634/5625/568
Acute kidney injuryRenal and urinary disorders4/5610/5632/5623/568
Cardiac failure congestiveCardiac disorders3/5612/5634/5624/568
BronchitisInfections and infestations0/5614/5631/5623/568
Cerebrovascular accidentNervous system disorders1/5614/5631/5621/568
Most frequent other events
Showing 10 of 13
Most frequent other events
EventBenra 10 mgBenra 30 mgBenra 100 mgPlacebo
Upper respiratory tract infectionInfections and infestations68/56171/56367/56265/568
BronchitisInfections and infestations66/56170/56363/56266/568
Viral upper respiratory tract infectionInfections and infestations61/56147/56360/56270/568
Urinary tract infectionInfections and infestations24/56124/56328/56218/568
HeadacheNervous system disorders19/56116/56327/56224/568
Lower respiratory tract infectionInfections and infestations26/56122/56315/56221/568
DyspnoeaRespiratory, thoracic and mediastinal disorders8/56110/56320/56224/568
Oral candidiasisInfections and infestations21/56112/56315/56212/568
HypertensionVascular disorders17/56116/56312/56221/568
InfluenzaInfections and infestations11/56120/56315/56211/568

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Benralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlaceboTotal
Mean64.7 ± 8.4765.6 ± 8.6165.0 ± 8.2365.3 ± 8.4465.2 ± 8.44
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlaceboTotal
Female196194207209806
Male3663683553591448
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Benralizumab 10 mgBenralizumab 30 mgBenralizumab 100 mgPlaceboTotal
White4414444434461774
Black or African American812161955
Asian70696767273
Other43373636152
09

Study locations

356 sites
  • Research Site
    Birmingham, Alabama 35216, United States
  • Research Site
    Gulf Shores, Alabama 36542, United States
  • Research Site
    Montgomery, Alabama 36117, United States
  • Research Site
    Flagstaff, Arizona 86001, United States
  • Research Site
    Phoenix, Arizona 85018, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Arcadia, California 91007, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Fresno, California 93721, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    Hawaiian Gardens, California 90716, United States
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Palmdale, California 93551, United States
  • Research Site
    Peninsula, California 90505, United States
  • Research Site
    Placentia, California 92870, United States
  • Research Site
    Rolling Hills Estates, California 90274, United States
  • Research Site
    Westminster, California 92683, United States
  • Research Site
    Centennial, Colorado 80112, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Denver, Colorado 80246, United States
  • Research Site
    Chiefland, Florida 32626, United States
  • Research Site
    Clearwater, Florida 33759, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Coconut Creek, Florida 33066, United States
  • Research Site
    Coral Gables, Florida 33134, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    DeBary, Florida 32713, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Doral, Florida 33172, United States
  • Research Site
    Edgewater, Florida 32132, United States
  • Research Site
    Fort Lauderdale, Florida 33308, United States
  • Research Site
    Hialeah, Florida 33010, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Hialeah, Florida 33013, United States
  • Research Site
    Homestead, Florida 33130, United States
  • Research Site
    Jacksonville, Florida 32204, United States
  • Research Site
    Kissimmee, Florida 34744, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33147, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Miami, Florida 33165, United States
  • Research Site
    Miami, Florida 33174, United States
  • Research Site
    Miami, Florida 33186, United States
  • Research Site
    Pensacola, Florida 32504, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Sarasota, Florida 34239, United States
  • Research Site
    South Miami, Florida 33143, United States
  • Research Site
    Atlanta, Georgia 30331, United States
  • Research Site
    Blue Ridge, Georgia 30513, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Woodstock, Georgia 30189, United States
  • Research Site
    Nampa, Idaho 83687, United States
  • Research Site
    Evergreen Park, Illinois 60805, United States
  • Research Site
    O'Fallon, Illinois 62269, United States
  • Research Site
    Peoria, Illinois 61602, United States
  • Research Site
    River Forest, Illinois 60305, United States
  • Research Site
    Topeka, Kansas 66606, United States
  • Research Site
    Henderson, Kentucky 42420, United States
  • Research Site
    Owensboro, Kentucky 42303, United States
  • Research Site
    Opelousas, Louisiana 70570, United States
  • Research Site
    Shreveport, Louisiana 71106, United States
  • Research Site
    Sunset, Louisiana 70584, United States
  • Research Site
    Bangor, Maine 04401, United States
  • Research Site
    Lutherville, Maryland 21093, United States
  • Research Site
    White Marsh, Maryland 21162, United States
  • Research Site
    Fall River, Massachusetts 02720, United States
  • Research Site
    Marlborough, Massachusetts 01752, United States
  • Research Site
    Buckley, Michigan 49620, United States
  • Research Site
    Kalamazoo, Michigan 49009, United States
  • Research Site
    Troy, Michigan 48085, United States
  • Research Site
    Edina, Minnesota 55435, United States
  • Research Site
    Fridley, Minnesota 55432, United States
  • Research Site
    Woodbury, Minnesota 55125, United States
  • Research Site
    Picayune, Mississippi 39466, United States
  • Research Site
    Port Gibson, Mississippi 39150, United States
  • Research Site
    Belton, Missouri 64012, United States
  • Research Site
    Florissant, Missouri 63033, United States
  • Research Site
    Saint Louis, Missouri 63136, United States
  • Research Site
    Missoula, Montana 59808, United States
  • Research Site
    Fremont, Nebraska 68025, United States
  • Research Site
    Omaha, Nebraska 68124, United States
  • Research Site
    Las Vegas, Nevada 89146, United States
  • Research Site
    Marlton, New Jersey 08053, United States
  • Research Site
    Union, New Jersey 07083, United States
  • Research Site
    Bronx, New York 10459, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    Brooklyn, New York 11236, United States
  • Research Site
    Great Neck, New York 11023, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    New Windsor, New York 12553, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Potsdam, New York 13676, United States
  • Research Site
    Burlington, North Carolina 27215, United States
  • Research Site
    Calabash, North Carolina 28467, United States
  • Research Site
    Charlotte, North Carolina 28277, United States
  • Research Site
    Hickory, North Carolina 28601, United States
  • Research Site
    Mooresville, North Carolina 28117, United States

Showing the first 100 of 356 sites across 26 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Criner GJ, Celli BR, Singh D, Agusti A, Papi A, Jison M, Makulova N, Shih VH, Brooks L, Barker P, Martin UJ, Newbold P. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2020 Feb;8(2):158-170. doi: 10.1016/S2213-2600(19)30338-8. Epub 2019 Sep 28. PubMed 31575508 ↗
  • Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramirez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. PubMed 31112385 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Apr 2018, 45 months.

Results were first posted in Jun 2019, 1 year 2 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 45 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2014
First posted
Jun 4, 2014
StartActual
Jun 25, 2014
Primary completionActual
Apr 9, 2018
CompletionActual
Apr 9, 2018
Results first posted
Jun 26, 2019
Last update
Jun 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02155660
Lead sponsor
AstraZeneca
Collaborators
MedImmune LLC
Responsible party
Sponsor
First posted
Jun 4, 2014
Start date
Jun 25, 2014
Primary completion
Apr 9, 2018
Completion
Apr 9, 2018
Results posted
Jun 26, 2019
Last update
Jun 26, 2019

Study contacts

Bartolome R. Celli, MD
principal investigator · Brigham and Women's Hospital, Pulmonary Division, 75 Francis Street, PBB Clinics 3, Boston, MA 02115

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion